Metabolomic Diagnostics is delighted to announce that CEO Robin Tuytten will present “The Biomarker Multiplexing Capabilities Of LC-MS Technology: The Key to Unlock Personalised Preeclampsia Risk Prediction Early in Pregnancy” for the American Association for Clinical Chemistry (AACC) on Jan 27th 2021. AACC  is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. Dr. Tuytten will discuss the current state-of-the art clinical applications in preeclampsia risk prediction. He will also discuss the intrinsic challenges of developing (biomarker based) risk predictors for syndromic conditions like pre-eclampsia and how these challenges impact biomarker development efforts.

Registration is free on the link below: